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ABSTRACT
The E7 oncoprotein of the high-risk human papillomavirus (HPV) plays a major role in HPV-induced carcinogenesis. E7 abro-
gates the G1 cell cycle checkpoint and induces genomic instability, but the mechanism is not fully understood. In this study, we
performed RNA sequencing (RNA-seq) to characterize the transcriptional profile of keratinocytes expressing HPV 16 (HPV-16)
E7. At the transcriptome level, 236 genes were differentially expressed between E7 and vector control cells. A subset of the differ-
entially expressed genes, most of them novel to E7-expressing cells, was further confirmed by real-time PCR. Of interest, the ac-
tivities of multiple transcription factors were altered in E7-expressing cells. Through bioinformatics analysis, pathways altered
in E7-expressing cells were investigated. The upregulated genes were enriched in cell cycle and DNA replication, as well as in the
DNAmetabolic process, transcription, DNA damage, DNA repair, and nucleotide metabolism. Specifically, we focused our stud-
ies on the gene encodingWDHD1 (WD repeat and highmobility group [HMG]-box DNA-binding protein), one of the genes that
was upregulated in E7-expressing cells. WDHD1 is a component of the replisome that regulates DNA replication. Recent studies
suggest thatWDHD1may also function as a DNA replication initiation factor as well as a G1 checkpoint regulator. We found
that in E7-expressing cells, the steady-state level ofWDHD1 protein was increased along with the half-life. Moreover, downregu-
lation ofWDHD1 reduced E7-induced G1 checkpoint abrogation and rereplication, demonstrating a novel function for
WDHD1. These studies shed light onmechanisms by which HPV induces genomic instability and have therapeutic implications.
IMPORTANCE
The high-risk HPV types induce cervical cancer and encode an E7 oncoprotein that plays a major role in HPV-induced carcino-
genesis. However, the mechanism by which E7 induces carcinogenesis is not fully understood; specific anti-HPV agents are not
available. In this study, we performed RNA-seq to characterize transcriptional profiling of keratinocytes expressing HPV-16 E7
and identified more than 200 genes that were differentially expressed between E7 and vector control cells. Through bioinformat-
ics analysis, pathways altered in E7-expressing cells were identified. Significantly, theWDHD1 gene, one of the genes that is up-
regulated in E7-expressing cells, was found to play an important role in E7-induced G1 checkpoint abrogation and rereplication.
These studies shed light onmechanisms by which HPV induces genomic instability and have therapeutic implications.
Human papillomaviruses (HPVs) are small DNA viruses thatreplicate in squamous epithelia. Specific types of HPV (high-
risk HPVs) are the causative agents for cervical and several other
cancers (1). The transforming properties of high-risk HPVs such
as HPV 16 (HPV-16) primarily depend on E7 as well as E6 onco-
genes (1, 2). HPV E6 and E7 proteins promote the degradation of
p53 and pRb, respectively (3, 4). E7 from the high-risk HPV types
can abrogate cell cycle checkpoints and induces genomic instabil-
ity. Although several transcription profiling studies for E7 have
been conducted usingDNAmicroarray analysis (3, 5–7), theHPV
E7 activities downstream from, or independent of, pRb responsi-
ble for deregulation of cell cycle and induction of genomic insta-
bility are not fully understood.
Cell cycle progression is regulated by cyclins and by cyclin-
dependent kinases (Cdks) and their regulatory proteins at sev-
eral checkpoints (8). Once the checkpoint becomes abnormal,
genomic instability may occur (8). Genomic instability is a hall-
mark of cancer progression (9). Polyploidy is a type of genomic
instability where cells have more than two sets of chromosomes
and has been recognized as a causal factor for tumorigenesis (10).
Significantly, polyploidy can be detected in the early stage of cer-
vical carcinogenesis (11). Polyploidy can be formed via rereplica-
tion, a process of successive rounds of host DNA replication with-
out entering mitosis (12). Rereplication may lead to not only
polyploidy but also gene amplification,DNA fragmentation,DNA
breaks, and cellular DNA damage response (13–15). We recently
demonstrated that HPV-16 E7 induces rereplication and that the
cellular DNA replication initiation factor Cdt1 plays a role in this
process (16).
DNA replication is regulated by sequential and interactive
mechanisms to ensure that the genome is accurately replicated
only once per cell cycle. The process of replication initiation is
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divided into two steps, pre-replicative complex (pre-RC) assem-
bly and activation; the latter leads to generation of replication
forks. Pre-RC starts with the association of the origin recognition
complex (ORC), which then promotes the recruitment of two
proteins, Cdc6 and Cdt1, onto origins. This is followed by recruit-
ment of minichromosome maintenance 2-7 (MCM2-7) onto
chromatin as a result of concerted actions of Cdc6 and Cdt1 (9).
Prior to the S phase, origins are licensed by the binding of com-
ponents of the replicativeDNAhelicaseMCMs in eukaryotes (17).
Afterward, licensing proteins are downregulated or inhibited such
that no more origins can be licensed and rereplication of DNA is
prevented. Cells employ a licensing checkpoint to monitor that
sufficient origins are licensed, inhibiting S-phase entry until that
state is established (18). The G1 arrest observed in cells that have
engaged in the licensing checkpoint is associated with low levels of
G1 Cdk-cyclin activity and pRb hypophosphorylation.
WDHD1 (WD repeat and high mobility group [HMG]-box
DNA-binding protein 1) containsmultipleN-terminalWD40 do-
mains and a C-terminal HMGbox.WD40 domains are found in a
variety of eukaryotic proteins and may function as adaptor/regu-
latorymodules in signal transduction, pre-mRNAprocessing, and
cytoskeleton assembly. HMG boxes are found inmany eukaryotic
proteins involved in chromatin assembly, transcription, and rep-
lication. In addition to its established role in pre-RC activation
(19–21), WDHD1 is also involved in pre-RC assembly (19). The
WDHD1 gene is localized adjacent to replication foci, interacts
with human primase-DNA polymerase/MCM10, and is required
for DNA synthesis (20, 22, 23). A role for WDHD1 in G1 check-
point control has recently been suggested (23). In addition, deple-
tion of WDHD-1 increases DNA damage, leading to the accumu-
lation of late S- and/or G2-phase cells (24).
In this study, we performed high-throughput RNA sequencing
(RNA-seq) to characterize the transcriptional profile of keratino-
cytes expressingHPV-16 E7. In E7-expressing cells, the expression
levels of hundreds of genes were found to be differentially regu-
lated, the activity ofmultiple transcription factors was altered, and
multiple molecular pathways were changed. TheWDHD1 gene is
among the genes upregulated in E7-expressing cells. Significantly,
downregulation of the WDHD1 gene reduced E7-induced G1
checkpoint abrogation and rereplication. These results should
help provide insights into the cellular pathways targeted during
tumor development caused by HPV.
MATERIALS AND METHODS
Cell culture. Primary human keratinocytes (PHKs) and spontaneously
immortalized human foreskin keratinocytes (NIKS cells) were cultured
on mitomycin C-treated J2-3T3 feeder cells with E medium composed of
3 parts Dulbecco’s modified Eagle medium (DMEM) and 1 part Ham’s
F12 medium plus 5% fetal bovine serum (FBS). Cells of the human telo-
merase reverse transcriptase-expressing human retinal pigment epithe-
lium cell line RPE1 were maintained in a 1:1 dilution of DMEM-Ham’s
F-12 medium plus 10% FBS. PHK and NIKS cells expressing HPV-16 E7
andRPE1 cells expressingHPV-16 E7 orHPV-6 E7were established using
a pBabe retroviral system as described previously (16). Populations of
infected cells were pooled and expanded. PHKs, NIKS cells, and RPE1-
derived cell lines were maintained in puromycin and used within 15 pas-
sages.
RNA-seq. Total RNA from NIKS cells was used to construct cDNA
libraries for RNA-seq. First, the rRNA was removed by the use of a Ribo-
Minus kit (Life Technologies) combined with custom-designed DNA
probes for rRNAs. The processed total RNA was then used to construct
RNA-seq libraries with a NEBNext mRNA library preparation kit (New
England BioLabs). In this way, double-stranded cDNA was synthesized
from rRNA-depleted total RNA. RNA was then end repaired, dA tailed,
and ligated to standard Illumina adaptor oligonucleotides. Adaptor-li-
gated cDNA libraries were amplified with Phusion PCR master mix. The
cDNA libraries were then loaded into a HiSeq 2000 system (Illumina) for
sequencing at the Washington University Genome Technology Access
Center. The resulting raw sequence reads were first analyzed using a cus-
tom bioinformatics pipeline to remove low-quality reads and then clus-
tered before sequentially mapping to the human transcriptome and ge-
nome with Bowtie was performed (25). In this way, about 90% of all
sequence reads weremapped to known human sequences. Sequence reads
mapping to the same transcript were combined and normalized on the
basis of the length of the transcript and the number of total reads from
each sample (reads per kilobase per million [RPKM]). Normalized read
counts were compared across samples to identify changes in transcript
abundance. Transcripts from the same gene locus in the human genome
were combined for evaluation of expression changes at the gene level.
Bioinformatics analysis. The official gene designations for the genes
that showed significant expression differences between E7 and vector cells
were submitted to the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID, v6.7) Bioinformatics Resources.Homo sapiens
were selected as the annotation species. Functional classification of differ-
entially expressed geneswas analyzed by gene ontology (GO) via the use of
the Web-based Gene Set Analysis Toolkit. Pathway analysis was per-
formed using the Kyoto Encyclopedia of Genes and Genomes (KEGG)
PATHWAY database via Web Gestalt. To identify the statistical signifi-
cance of the cluster results, we set a P value of0.05 as the cluster filter.
We then used the gene counts and terms to make the column chart sepa-
rately for each category.
RT-PCR. Total RNA from RPE1, NIKS, and PHK control cells and
the corresponding E7-expressing cells was isolated using an RNeasy kit
(Qiagen) according to the manufacturer’s instruction. cDNAwas synthe-
sized with a Superscript VILO cDNA synthesis kit (Invitrogen). iTaqUni-
versal SYBR green Supermix (Bio-Rad) was used in a Bio-Rad CFX96
Touch Real-Time PCR detection system for quantitative real-time PCR
(qRT-PCR). Data were analyzed using the threshold cycle (2CT)
method. The primer sequences are listed in Table 1.
ChIP assay. The chromatin immunoprecipitation (ChIP) assay was
performed using a ChIP assay kit from Millipore, following the supplied
protocol. Immunoprecipitations were performed using anti-MCM3 or
control IgG antibodies. PCR was performed with the primers designed
from the sequences of the human c-MYC gene as follows: sense, AAG
CTGAATTGTGCAGTGCATC; antisense, CTCACCCAAAGGCATTTT
AAG. It was shown that the MCM protein complex binds to the DNA
replication initiation zone upstream of the c-MYC gene (26).
Flow cytometry. For cell cycle and polyploidy analysis, asynchronous
cultured cells expressing HPV E7 or vector alone were treated with phos-
phate-buffered saline (PBS) or bleomycin (Alexis Biochemicals) (4g/ml
in PBS). At 24 h later, cells were fixed in 70% ethanol, treated with 50
g/ml RNase A plus 50 g/ml propidium iodide, and analyzed by fluo-
rescence-activated cell sorting (FACS). For the bromodeoxyuridine
(BrdU) labeling experiment, BrdU (final concentration, 20 M) was
added to the medium 2 h before collection of cells. After fixation, cells
were permeabilized with 2 N HCl–0.5% Triton X-100, neutralized with
0.1 M sodium tetraborate, stained with monoclonal anti-BrdU (BD Bio-
sciences) followed by treatment with anti-mouse IgG F(ab)2-fluorescein
isothiocyanate (FITC) (Sigma), and counterstained with PBS–7-amino-
actinomycin D (7-AAD)–RNase A. Flow cytometric analysis was per-
formed on a BD FACSAria III sorter instrument equipped with BD
FACSDiva 7.0 software (BD Biosciences, NJ, USA). FITC 490-nm fluo-
rescence was acquired in logarithmic amplification in FL1, and 7-AAD
650-nm fluorescence was acquired in linear amplification in FL3. Cell
cycle analysis was done using a Cytomics FC500 Flow Cytometry CXP 2.0
system.
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siRNAs and transfection. Cells were transfected with a final concen-
tration of 20 nM small interfering RNA (siRNA) per target gene using
Lipofectamine 2000 transfection reagent (Invitrogen) according to the
manufacturer’s instructions. For gene knockdown analysis, cells were har-
vested 48 h posttransfection and specific protein levels were analyzed by
immunoblotting. For cell cycle analysis, 24 h after transfection, cells were
treated with bleomycin (4 g/ml) for an additional 24 h. For polyploidy
analysis, cells were blocked in G1 phase with thymidine for 16 h after
transfection with 20 nM siRNA for 24 h, and then cells were treated with
bleomycin (4 g/ml) for an additional 48 h. The siRNA duplexes were
as follows: for the small interfering WDHD1-1 (si-WDHD1-1) sense
strand, 5=-GCAUGUACCCUAAGAAUAA-3=; for the si-WDHD1-2
sense strand, 5=-GCAAAGUUAUGGAAAGUAU-3=; for the si-MCM3
sense strand, 5=-GCATTGTCACTAAATGTTCTCTAGT-3= (27); and
for the negative-control (NC) siRNA sense strand, 5=-UUCUCCGAA
CGUGUCACGU-3=.
Immunoblotting. Total cellular protein was prepared in lysis buffer
(10 mM Tris [pH 7.4], 1% SDS, 1.0 mM sodium orthovanadate). To
obtain cytoplasmic and nuclear proteins, cells were extracted with a nu-
clear extract kit (Active motif; 100946). The protein concentration was
measured by the use of bicinchoninic acid (BCA) protein assay reagent
(Pierce) and confirmed by Coomassie blue staining of membranes after
blotting. Equal amounts of protein from each cell lysate were separated in
an SDS polyacrylamide gel (PAGE) and transferred onto a nitrocellulose
filter membrane (NC) membrane. Membranes were blotted with anti-
bodies againstWDHD1 (abcam; ab72436), MCM3 (abcam; ab4460), SP1
(Cell Signaling; catalog no. 9389), and tubulin (Sigma; T-4026). Protein
bands were detected using an Odyssey infrared imaging system (Li-COR,
Lincoln, NE) and quantified using ImageJ (NIH). WDHD1 half-life was
measured following a cycloheximide (25 g/ml) chase procedure and
calculated using Half Life Calculator (www.calculator.net).
Statistical analysis. Data are presented as means and standard devia-
tions (SDs). The Student t test was used to evaluate the differences be-
tween means. P values of0.05 were considered significant.
RESULTS
Gene expression profiling of HPV-16 E7-expressing cells. To
identify genes differentially expressed between cells with andwith-
out E7, we used NIKS cells (28). NIKS cells exhibit many charac-
teristics of early-passage human keratinocytes, the natural host
cells for HPV, including stratification, differentiation, and the
ability to sustain the HPV life cycle (29–31). The use of NIKS cells
for HPV oncogene studies can avoid comparisons being made
between senescing (vector) and proliferating (E7) cells, when the
experimental goal is to explore the biological activities of E7. In
addition, while PHKs do not proliferate efficiently, NIKS cells
grow relatively well in culture. For gene expression profiling anal-
ysis, the RNA-seq approach was used. From RNA-seq data, we
detected a total of 20,537 transcripts that included 17,090mRNAs.
After normalization, 237 genes were identified that were differen-
tially expressed between E7-expressing and vector control NIKS
cells (Fig. 1A). Among these, 150 genes were upregulated (be-
tween 1.7-fold and 4.3-fold) and 87 genes were downregulated
(between 1.7-fold and 4.3-fold) in NIKS cells expressing E7 (Fig.
1A; see also Table S1 in the supplemental material).
To verify the RNA-seq results, we performed real-time PCR
assay for nearly a dozen genes selected on the basis of their poten-
tial E7-related biological functions. Among these genes, consistent
with RNA-seq analysis results, the WDHD1, UHRF1, CHAF1B,
ASF1B, MRE11, MELK, HMMR, and DEK genes were shown to
be upregulated whereas the FN1 (fibronectin), UBE2L6, and
TIMP1 genes were shown to be downregulated in E7-expressing
NIKS cells (Fig. 1B). For example, the WDHD1 (WD repeat and
HMG-box DNA-binding protein 1) gene was shown to be up-
regulated by more than 2-fold in E7-expressing NIKS cells by
RNA-seq and it was verified to be similarly upregulated by real-
time PCR; the UBE2L6 (ubiquitin/ISG15-conjugating enzyme E2
L6) gene was shown to be downregulated by 1.77-fold in E7-ex-
pressing NIKS cells by RNA-seq, and it was verified to be similarly
downregulated by real-time PCR. Although the fold changes as
demonstrated by real-time PCR for some genes such as those en-
coding CHAF1B and FN1 were not dramatic, the differences are
statistically significant. These are newly described differentially
expressed genes in E7-expressing cells, with the exception of the
DEK and FN1 genes. Thus, the RNA-seq results provided ge-
nome-wide gene expression profiling in E7-expressing cells that
can be verified by real-time PCR.
Using real-time PCR, we also examined the expression of the
selected genes described above in primary human keratinocytes
(PHKs) expressingHPV-16 E7 or containing a vector. The expres-
sion profiles of the selected genes were similar to what was ob-
served in NIKS cells (Fig. 1B). However, the opposite results were
obtained for FN1 expression. While FN1 was downregulated in
E7-expressing NIKS cells, it was upregulated in E7-expressing
TABLE 1 The primer sequences
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PHKs. It was previously reported that FN1 was downregulated in
three immortal nontumorigenic cell lines that expressed the high-
risk HPV E7 protein (32). These results show that the expression
profiles for the selected genes are similar, with the exception of the
expression profiles of NIKS cells and PHKs expressing HPV E7.
Functional implications of differentially expressed genes in
HPV E7-expressing cells. Some of the differentially expressed
genes in E7-expressing cells identified in this study have previ-
ously been shown to be regulated by HPV E7 at the transcription
level. These genes are summarized in Table 2. E7 is known to
abrogate cell cycle checkpoints. Consistent with this notion, a
group of cell cycle-related genes are differentially expressed in
E7-expressing cells. These include the CCNA2, Cdc25A, and
MYBL2 genes. Expression of the CCNA2 gene, which encodes
cyclin A2, is upregulated in E7-expressing cells (51). The tyrosine
phosphatase Cdc25A gene is an E2F1 target gene (52) and is in-
volved in the regulation of the G1/S-phase transition (53). The
Cdc25A gene is upregulated in E7-expressing cells (54, 55, 57).
The MYBL2 (B-Myb) gene is an E2F-responsive gene and a com-
ponent of theDREAMcomplex that promotes expression of genes
during the G2/M phase of the cell cycle (48). B-Myb has been
implicated in a positive regulatory role for Cdk1 expression (49,
56).We and others have shown that E7 upregulatesB-Myb expres-
sion (7, 46). Moreover, downregulation of B-Myb-induced G1 ar-
rest in E7-expressing cells upon DNA damage has been described
previously (59).
Some other genes such as the APOBEC-3B, BARD1, DEK,
DHFR,MSH6, RAD51AP1, S100P, and S100A8 genes are upregu-
lated in E7-expressing cells and may play critical roles in cervical
carcinogenesis. Among these genes, the APOBEC-3B gene, a
member of the cytidine deaminase gene family, is activated by
HPV infection and increases genome instability (46). The nuclear
proteinDEKhas shown to be upregulated in E7-expressing cells as
well as cervical intraepithelial neoplasia (CIN) and cervical can-
cers.DEKwas reported to be required for cellular immortalization
byHPVE7 (47, 48). DEKupregulationmay be a common event in
FIG1 Genes differentially expressed inHPV-16 E7-expressing cells. (A)Numbers of genes differentially expressed betweenNIKS cells expressing E7 and a vector
control, as determined by RNA-seq, are presented as columns. Blue, total number of protein-coding mRNAs detected; red, upregulated genes in E7-expressing
cells; green, downregulated genes in E7-expressing cells. (B) Real-time PCR assay for selected genes in keratinocytes. Upper panel, relative expression levels of
mRNAs in E7-expressingNIKS cells or PHKs comparedwith vector,measured by real-time PCR andRNA-seq. Lower panels, images ofDNAgel electrophoresis.
MWM, molecular weight marker.
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human carcinogenesis and may reflect its senescence inhibitory
function (47). The RAD51AP1 gene (a DNA repair gene) is an
S-phase cell cycle checkpoint gene that is directly induced by E2F1
and becomes overexpressed when pRB is inactivated by E7 (49).
Bioinformatic analysis of genes differentially expressed in
E7-expressing cells. We next performed bioinformatics analysis
on genes differentially expressed in E7-expressing cells. First we
used the Gene Ontology (GO) system, a gene function classifica-
tion system that provides a comprehensive description of gene
properties (60). Based on the GO annotation, the 150 upregulated
genes could be classified intomultiple functional groups (Fig. 2A).
In the “biological processes” category, more than 50 genes be-
longed to the “cell cycle” functional group. Some additional cell
cycle-related genes were in the “M phase,” “cell division,” and
“cell proliferation” functional groups. Taking the data together,
after eliminating overlapping genes, a total of 59 geneswere shown
to be cell cycle related. These results are consistent with the known
cell cycle regulatory functions ofHPVE7 (61). Interestingly,more
than 40upregulated genes in E7-expressing cells were in the “DNA
metabolic process” (such as DNA repair and replication) group.
In addition, 33 upregulated genes belonged to the “DNA replica-
tion” functional group, which is consistent with the known func-
tion of E7 to establish an S-phase-like environment in otherwise
differentiating epithelial cells to support HPV replication (62).
There were also 41 genes and 28 genes, respectively, in the “regu-
lation of transcription” and “transcription” functional groups. It






S100P 4.27 1 (50, 52) S100 calcium binding protein P
DHFR 3.54 1 (53) Dihydrofolate reductase
CDC6 3.00 1 (54) Cell division cycle 6
RAD51AP1 1.98 1 (55) RAD51-associated protein 1
APOBEC3B 1.97 1 (47) Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3B
DEK 1.80 1 (48, 49) DEK oncogene
CDC25A 1.82 1 (56) Cell division cycle 25A
MSH6 1.78 1 (57) MutS homolog 6
CCNA2 1.78 1 (57) Cyclin A2
BARD1 1.77 1 (59) BRCA1-associated RING domain 1
MYBL2 1.79 1 (7, 46) V-myb myeloblastosis viral oncogene homolog (avian)-like 2
S100A8 1.70 1 (58) S100 calcium binding protein A8
FN1 0.50 2 (59) Fibronectin 1
a Upward-pointing arrows represent upregulation; downward-pointing arrows represent downregulation.
FIG 2 GO categories of differentially expressed genes inNIKS cells expressingHPV-16 E7. (A) Biological process category. Ten groups (withmore than 22 genes
each) of upregulated genes (n 157) are listed. (B) Biological process category. Three groups (with more than 10 genes each) of downregulated genes (n 67)
are listed.
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is known that E7 is involved in transcriptional regulation, partly
through degradation of pRb and release of E2F.
E7 has been known to regulate theDNAdamage response (16).
In fact, E7 also inducesDNAdamage (63, 64). Consistently, a total
of 30 genes that were upregulated in E7-expressing cells belonged
to the “cellular response to stress,” “response to DNA damage
stimulus,” and “DNA repair” groups. In addition, a total of 30
genes belonged to the “chromosome organization” group and 24
genes belonged to the “organelle fission” group (the members of
which are employed to obtain a variety of organelles in cell divi-
sion). The significance of the latter two groups to E7 function
remains to be established.
Interestingly, genes in a group related to “regulation of cata-
bolic process” were downregulated in E7-expressing cells (Fig.
2B). Genes for “endoderm development” were also downregu-
lated in E7-expressing cells. However, the significance of these
findings is not known.Notably, antiapoptotic genes in the “induc-
tion of programmed cell death” functional group are also down-
regulated in E7-expressing cells. Cells expressing HPV-16 E7 are
predisposed to undergo apoptosis (65, 66), and the observation is
therefore consistent with this finding.
Next, we searched the differentially expressed genes using the
KEGG PATHWAY database, a collection of pathway maps repre-
senting knowledge on themolecular interaction and reaction net-
works. Nine biological pathways that were significantly upregu-
lated (6 or more genes with altered expression) in E7-expressing
NIKS cells are listed in Table 3. Consistent with results of GO
analysis and the known E7 functions, the “cell cycle” and “DNA
replication” pathways were significantly regulated in E7-express-
ing cells. As expected, the members of the “pathways in cancer”
group were changed. Up to 24% of upregulated genes were asso-
ciated with DNA repair (“mismatch repair,” “nucleotide excision
repair,” and “homologous recombination” groups), and 12% of
upregulated genes were associated with nucleotide metabolism
(“purine metabolism” and “pyrimidine metabolism” groups). In
addition, 6% of upregulated genes are in the “p53 signaling path-
way” group (data not shown).
Targets of specific transcription factors are differentially ex-
pressed in HPV E7-expressing cells. We reasoned that, on the
basis of the results seen with differentially expressed genes, we
might be able to identify transcription factors whose activities are
differentially regulated in E7-expressing cells. For this, we ana-
lyzed 41 of the cancer-related transcription factor families de-
scribed in TRED (https://cb.utdallas.edu/cgi-bin/TRED/tred.cgi
?processsearchTFGeneForm) for their predicted target gene
expression characteristics. Significantly, targets of the transcrip-
tion family that includes E2F,MYB,MYC,NF-B, p53, and SP are
significantly differentially expressed (with at least 10 target genes
that were up- or downregulated) in E7-expressing cells (Fig. 3).
E7 targets the degradation of pRb and release of E2F1. E7 may
also activate E2F2 transcription through interaction with HDACs
(67). In contrast, E7 can associate with and inactivate the tran-
scriptional repression activity of E2F6 (68). Consistent with these
observations, as many as 24 target genes of the E2F family are
upregulated in E7-expressing cells.
The MYB gene family consists of three members, namely, A-,
B-, and C-Myb. Multiple lines of evidence suggest that B-Myb
plays an important role in HPV-associated carcinogenesis (7, 42,
69–71). We recently showed that HPV E7 is able to activate the
B-Myb gene (42, 44, 45).
Up to 17MYC targets were upregulated in E7-expressing cells.
This is consistent with the observation that HPV-18 E7 binds and
TABLE 3 KEGG pathway analysis of differentially expressed genes in E7-expressing cells
Pathway IDa KEGG pathway(s) Total no. of genes Highly expressed genes
04110 Cell cycle 20 E2F1, CDC6/7/25A/45, CDK1/2, RBL1, TTK, MCM27, CCNE2, CDKN2A,
PCNA, MDM2, CCNA2
03030 DNA replication 15 POLE, POLA1, MCM2–7, RPA1, RFC5, POLD3, PRIM1, RPA2, RFC3, PCNA
05200 Cancer (several pathways) 9 E2F1, CCNE2, MSH6, CDKN2A, MSH2, MDM2, BRCA2, BIRC3, CDK2
03430 Mismatch repair 8 POLD3, RFC5, RPA1, MSH6, RPA2, RFC3, MSH2, PCNA
03420 Nucleotide excision repair 7 POLD3, RFC5, RPA1, RPA2, RFC3, POLE, PCNA
04115 p53 signaling 6 CCNE2, CDK1, CDKN2A, RRM2, MDM2, CDK2
03440 Homologous recombination 6 POLD3, RPA1, RPA2, MRE11A, BRCA2, RAD54B
00230 Purine metabolism 6 POLD3, PRIM1, RRM2, RRM1, POLE, POLA1
00240 Pyrimidine metabolism 6 POLD3, PRIM1, RRM2, RRM1, POLE, POLA1
a ID, identifier.
FIG 3 Differentially expressed transcription factor target gene families in HPV E7-expressing cells. Genes differentially expressed between NIKS-E7 and
NIKS-vector cells are categorized as targets of transcription factors. y axis, numbers of differentially expressed genes. x axis, names of transcription factor gene
families.
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augments c-Myc transcriptional activity (72). We have also dem-
onstrated that activation of c-Myc contributes to bovine papillo-
mavirus type 1 E7-induced cell proliferation (73). Nonetheless,
the results cannot rule out the possibility that upregulation of
MYC targets is an indirect effect of E2F, as most (9 of 17) of the
upregulated MYC targets are also E2F targets.
Interestingly, most (10 of 14) of the targets of NF-B family
were downregulated in E7-expressing cells. NF-B plays a key role
in regulating the immune response to infection. Abnormal regu-
lation of NF-B has been linked to cancer, viral infection, and
improper immune development. Inhibition of NF-Bmay reflect
the function of HPV to downregulate the immune system. Con-
sistently, HPV-16 E7 inhibited NF-B DNA binding activity (74)
and attenuated NF-B activation (75, 76). However, and in con-
trast, it was observed that E7, together with E6, upregulated NF-
B-responsive genes (77). Regulation of NF-B activity by E7 can
be complicated, depending on the cellular context.
Results from several studies indicate that in HPV E7-express-
ing cells, the activity of p53 is inhibited, although its steady-state
level is high (78–81). However, results of one study suggest that
p53 remains active in E7-expressing cells (82). The p53 family
targets include p53, p63, and p73. Some were not confirmed (data
not shown). Among the experimentally confirmed p53 targets, all
three genes that are positively regulated by p53 (the MDM2,
MSH2, and S100A9 genes) were upregulated in E7-expressing
cells whereas the one gene negatively regulated by p53, the
PTHLH gene (encoding parathyroid hormone-related protein),
was downregulated. These results favor the notion that p53 func-
tions in E7-expressing cells.
The Sp family transcription factors are widely expressed in hu-
man tissues and involved in the regulation of multiple cellular
processes and responses to cellular microenvironment. We know
little about the functional interaction of HPV with Sp family
members other than SP1 binding to theHPV early promoter (83).
Interestingly, we found that most of the transcriptional targets of
Sp family members were downregulated in E7-expressing cells
(Fig. 3).
Expression and localization of WDHD1 in E7-expressing
cells. Given the fact that cell cycle and DNA replication pathways
and their related genes have shown significant disregulation in
E7-expressing cells, we selected WDHD1, which is known to be
involved in both DNA replication and potentially G1 checkpoint
regulation, for further analysis. As transfection efficiencies in ke-
ratinocytes are not very high, we included RPE1 cells. RPE1 cells
expressing the wild-type E7 (RPE1-E7) and vector control (RPE1-
vector) have been used in our recentHPV-related functional stud-
ies (16, 84, 85). Similarly to what was observed in keratinocytes,
WDHD1mRNA levels were increased (2-fold) in E7-expressing
FIG 4 Upregulation and nuclear localization ofWDHD1 in E7-expressing cells. (A)WDHD1mRNA levels in RPE1 cells determined by real-time PCR analysis.
(B) WDHD1 protein levels in RPE1 and NIKS cells expressing E7 or vector examined by Western blotting (left panel). WDHD1 mRNA levels in RPE1 cells
expressing HPV-6 E7 or 16 E7 (right panel) are indicated. gapdh, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene. (C) Cellular localization of
WDHD1 in E7-expressing cells. Right panel, quantification of WDHD1 protein expression in different cellular compartment. Error bars reflect the standard
deviations of the means. Data from an experiment representative of 3 are shown. *, P 0.05.
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FIG 5 WDHD1 plays a role at the G1/S transition in E7-expressing cells. (A) RPE1 cells expressing E7 or containing a vector were transfected with siRNAs
targetingWDHD1. The steady-state levels ofWDHD1were measured byWestern blotting. Tubulin was used as a loading control. Right panel, quantification of
relative WDHD1 levels from 3 independent experiments. (B) RPE1 cells were incubated with cycloheximide (CHX) and harvested at the indicated times. The
stability of WDHD1 was monitored by immunoblotting analyses (left panel). Data are summarized in the right panel. (C) After siRNA transfection, cells were
treatedwith bleomycin, stainedwith propidium iodide (PI), and analyzed by flow cytometry. Results of 1 experiment representative of 3 are shown (upper panel).
The percentages of cells with 2C and 4CDNAcontent are indicated.Data are summarized in the lower panel. (D)After siRNA transfection, cells were treatedwith
bleomycin, stained with BrdU, and analyzed by flow cytometry. Data of 3 independent experiments are summarized in the lower panel. *, P 0.05; **, P 0.01.
NC, negative control.
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RPE1 cells (Fig. 4A). We then further examined the steady-state
level of WDHD1 protein. As shown in Fig. 4B, the levels of
WDHD1 protein were upregulated in both RPE1-E7 cells (1.9-
fold) and NIKS-E7 cells (2.2-fold). As an initial step toward un-
derstanding the mechanism by which E7 regulates WDHD1, we
examined the steady-state level of WDHD1 protein in RPE1 cells
expressingHPV-6 E7, which does not degrade pRb (86). As shown
in Fig. 4B, the level of WDHD1 protein was comparable to that
seenwith the vector control cells, suggesting that pRb degradation
is important for WDHD1 upregulation by HPV E7.
WDHD1 is usually localized in the nucleus adjacent to replica-
tion foci and is required for efficient DNA replication (24, 87).We
examined cellular localization ofWDHD1 in E7-expressing RPE1
cells. Our study demonstrated thatWDHD1wasmainly located in
the nucleus, where it was present in levels that were about 2-fold
higher in E7-expressing cells than in control cells (Fig. 4C).
WDHD1 depletion induces G1 arrest. Many HMG proteins
facilitate the assembly of nucleoprotein complexes to influence
cell cycle (23–25). DNA replication initiation factors may also be
involved in the licensing checkpoint to modulate S-phase entry
(18). As an HMG box-containing protein and a DNA replication
initiation factor, WDHD1 may play a role in cell cycle control in
E7-expressing cells. To test this possibility, we employed the RNA
interference (RNAi) approach by using two independent siRNAs.
The steady-state level of WDHD1 protein was downregulated (to
0.2-fold) after transfection with si-WDHD1-2 and (to 0.5-fold)
after transfection with si-WDHD1-1 in RPE1-E7 cells (Fig. 5A).
We also determined the protein stability of WDHD1 in E7-ex-
pressing cells. Two hours after cycloheximide treatment, the
steady-state level of WDHD1 in the vector-containing RPE1 cells
had dropped by more than 50%. In contrast, 75% of WDHD1
was maintained in E7-expressing cells (Fig. 5B). The protein half-
life of WDHD1 in E7-expressing cells was greatly increased com-
pared with that in the vector control cells (3.4 h versus 1.6 h).
Next, we examined changes of cell cycle profiles of E7-expressing
and vector-containing RPE1 cells after siRNA knockdown of
WDHD1. Consistent with what we have recently observed, upon
treatment using the DNA-damaging agent bleomycin, fewer cells
were arrested at the G1 phase in the nonsilencing siRNA control-
transfected E7-expressing cells than in the vector control cells (Fig.
5C), indicating abrogation of the G1 checkpoint in E7-expressing
cells. Notably, knockdown of WDHD1 with siRNAs led to an in-
crease in the G1 peak (from 26.9% to 67.5% for si-WDHD1-1 and
46.7% for si-WDHD1-2) in E7-expressing cells. To demonstrate
the role of WDHD1 in promoting S-phase entry of cells more
directly, we transfected siRNAs targeting WDHD1 into E7-ex-
pressing cells andmeasured BrdU incorporation upon bleomycin
treatment. Significantly, knockdown ofWDHD1 by siRNAs led to
a significant reduction of BrdU incorporation (from 13.7% to
5.3% for si-WDHD1-1 and 5.7% for si-WDHD1-2) in RPE1-E7
cells (Fig. 5D). These results demonstrate an important role of
WDHD1 in the G1 cell cycle control and S-phase entry of E7-
expressing cells.
WDHD1 depletion reduces rereplication in E7-expressing
cells. We have recently demonstrated that cells expressing
HPV-16 E7 undergo rereplication upon DNA damage and that
the DNA replication-initiating factor Cdt1 plays an important
role in this process (16). Since WDHD1 has been implicated as a
DNA replication-initiating factor (22), we examined its potential
role in E7-induced rereplication. As WDHD1 depletion may
block cells at theG1/S phase, we synchronized cells with thymidine
and then released them into S phase and G2 phase (Fig. 6A). As
shown in Fig. 6A, after thymidine release for 2 h, 30% of the cells
synchronized in G1 bypassed S phase and entered G2 phase and
6% became polyploid. As time passed, 60% of cells entered G2
phase and 8% became polyploid by 6 h, suggesting that rereplica-
FIG 5 continued
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FIG 6 WDHD1 depletion reduces rereplication and decreases MCM3 chromatin loading and expression. (A) RPE1-E7 cells were treated with thymidine for 16 h,
harvested at different times after release from thymidine, and analyzed with flow cytometry. (B) RPE1-E7 cells were transfected with siRNAs targeting WDHD1 and
treatedwith thymidine for 16 h followed by bleomycin treatment for 48 h after release for 2 h from thymidine. Cells were analyzedwith flow cytometry. Cells with	4C
DNAcontentwere quantified (right panel). (C) RPE1 cells were subjected toChIP assay using antibody againstMCM3 (left panel). RPE1-E7 cells were transfectedwith
siRNA targetingWDHD1 and cells were subjected to ChIP assay (right panel). (D) RPE1-E7 cells were transfected with siRNAs targetingWDHD1, and real-time PCR
analysis was performed. Another set of cells (right panel) was analyzed for steady-state levels of MCM3 by Western blotting. (E) RPE1-E7 cells were transfected with
siRNAs targetingMCM3.Cells with	4CDNAcontent were quantified (right panel). Data from an experiment representative of 3 are shown. *,P 0.05; **,P 0.01.
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tion had occurred. We then used siRNAs to assess the role of
WDHD1 in E7-induced rereplication upon DNA damage. Nota-
bly, the percentage of polyploidy was significantly reduced in E7-
expressing cells after WDHD1 knockdown (Fig. 6B). Our recent
study demonstrated that, under those conditions, polyploidy in
E7-expressing cells was due to rereplication, where DNA replica-
tion occurs once again in the G2 phase of the cell cycle (88). These
results indicate that WDHD1 plays an important role in E7-in-
duced rereplication.
As an initial step toward understanding the mechanism by
which WDHD1 knockdown causes a reduction in rereplication,
we examined the loading of MCM3 onto chromatin by ChIP as-
say. It is known that DNA replication-initiating factors recruit
MCMs to the origin of replication (89). Consistent with this no-
tion, more MCM3 (2.5-fold) bound to chromatin in E7-ex-
pressing cells than in vector control cells (Fig. 6C, left panel).
WDHD1 knockdown by siRNA significantly reduced MCM3
loading to the chromatin (Fig. 6C, right panel). Next, we exam-
ined the effect of knocking downWDHD1 onMCM3 expression.
As shown in Fig. 6D, both MCM3 mRNA levels (left panel) and
the steady-state levels ofMCM3went down afterWDHD1 knock-
down. In addition, WDHD1 knockdown significantly reduced
polyploidy (Fig. 6E). These results indicate that WDHD1 facili-
tates rereplication in E7-expressing cells by modulating MCM3,
via either expression or loading. The extent to which the reduced
MCM3 chromatin levels seen after WDHD1 knockdown are due
to loading per se or to its expression remains to be determined.
DISCUSSION
Previous transcriptional profiles of E7 were mostly determined in
the presence of E6. Nonetheless, several gene expression profiling
studies have been conducted on HPV E7-expressing cells using
microarray analysis. The cells employed includedmouse cells, cer-
vical cancer cell lines (C33A and CaSki), and PHKs (3, 5–7, 90).
However, there are major limitations with the DNA microarray
approach, such as the relatively high background noise resulting
from solution-based DNA probe hybridization as well as the lim-
ited scope of profiling analysis, which is confined by the DNA
probe set. RNA-seq is a more sensitive method for reliably iden-
tifying differentially expressed genes, especially low-abundance
genes, than traditional methods for transcriptome profiling such
as microarray analyses (91). Additionally, RNA-seq profiling is
more comprehensive than microarray analyses, as all expressed
transcripts in the cells are included in the analysis. Our study was
the first to profile the gene expression of HPV E7-expressing cells
using RNA-seq. With this new method, we have identified many
E7-induced gene expression changes that were not reported pre-
viously from microarray studies.
It was observed that although the steady-state level of p53 was
high inHPVE7-expressing cells, its activity was low (78, 80, 92). It
was therefore proposed that p53 activity is inhibited by HPV E7.
However, one study found the opposite phenomenon (82). Is p53
functioning in E7-expressing cells? This is an open question and
remains to be resolved. Using an unbiased approach, we showed
that among the experimentally confirmed p53 targets, all genes
positively regulated by p53 were upregulated in E7-expressing
cells while the one negatively regulated by p53 (the PTHLH gene)
(93) was downregulated. These results favor the notion that p53 is
functional in E7-expressing cells. Consistently, up to 6% of the
upregulated genes identified in this study have been shown to
participate in the p53 signaling pathway (data not shown).
While the established cellular function is pre-RC activation for
DNA synthesis, WDHD1 has also been implicated in a role in
pre-RC assembly, functioning as a DNA replication initiation fac-
tor (19). The knownDNA replication initiation factors, Cdt1 and
Cdc6, have been shown to be required for rereplication (9, 10,
14, 34, 44, 63). However, no such function has been reported
for WDHD1. The current study was the first to demonstrate
that WDHD1 plays a role in rereplication. The mechanism by
which WDHD1 contributes to rereplication is likely that of load-
ing MCMs. Consistent with this notion and with a previous ob-
servation, we have shown that WDHD1 knockdown reduced
chromatin loading ofMCM3. Interestingly,WDHD1 knockdown
reduced both MCM3 expression and its chromatin loading. It is
therefore not clear whether the reduced chromatin loading of
MCM3 after WDHD1 knockdown is a result of reduced MCM3
expression or of loading to chromatin or of a combination of the
two. The detailedmechanismbywhichWDHD1 regulatesMCM3
expression is also not known. Future studieswill address this ques-
tion.
DNA replication initiation factors have been shown to play a
role in G1 checkpoint regulation. Consistently, we have shown
that knockdown of WDHD1 led to G1 arrest in E7-expressing
cells. It is believed that G1 arrest induced by knockdown of DNA
replication-initiating factors is due to their requirement for DNA
replication initiation. This is normally associated with reduced
cyclin D and cyclin E activities (94). Interestingly, our study
showed that cells still arrested in the G1 phase even with partial
knockdown ofWDHD1 (Fig. 5). In this case, the steady-state level
ofWDHD1 after knockdown in E7-expressing cells was similar to
that seen with the NC-transfected control cells, where normal
DNA replication is expected, suggesting that WDHD1 regulates
the G1 checkpoint in E7-expressing cells by a mechanism inde-
pendent of DNA replication initiation. Consistently, mimosine
can prevent WDHD1 binding to chromosomes and arrest the
cell cycle in the G1 phase by activating HIF1- (23). How
WDHD1 precisely regulates the G1 checkpoint requires further
studies.
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